Two clinical features of ulcer disease (and related, or associated, diseases such as oesophagitis) are of cardinal importance in determining the nature of anti-ulcer therapy -the tendency of the disease to relapse and the likelihood that repeated relapses will occur for many years: perhaps throughout the lifetime of many patients. At some time during the life of patients with an ulcer, relapse results in haemorrhage in one-third of affected individuals2 and in perforation in about 10%3 so that any relapse is potentially lethal. The aim of the treatment of ulcer disease must therefore be to prevent relapse.
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At present there is no drug therapy which 'cures' ulcer disease -that is, there is no treatment which is not followed by relapse of the ulcers when treatment is discontinued. On the other hand, it has been repeatedly shown recently that continuous treatment with the H2 receptor antagonist cimetidine4 or ranitidine5 6can maintain ulcers in remission while other, albeit shorter, studies indicate that continuous treatment with pirenzepine7 8 and sucralphate9 10 can also keep ulcers healed. Even continuous administration of the presently available anti-ulcer drugs for more than five years, however, does not seem to have altered the underlying tendency of ulcers to relapse when treatment is stopped. It seems, therefore that long-term continuous treatment with drugs prevents ulcer relapse only if given for many years and perhaps for life.
to general toxicity, however, other problems can be predicted from the specific pharmacological actions of anti-ulcer drugs and these must also be properly evaluated. The most important of these effects is the inhibition of gastric secretion by action on the gastric parietal cells, an effect which is achieved by blockade of specific receptors, such as the histamine H2 receptor (cimetidine, ranitidine), or gastric muscarinic receptor (pirenzepine), or by inhibiting intracellular messengers (polycyclic drugs such as trimipramine, mianserin, quisultidine), or by interfering with the specific processes involved in the secretion of acid (substituted benzimidazoles, such as omeprazole, which inhibit the K+.H+-ATPase of the parietal cells).
The gastric secretory inhibitors may give rise not only to drug-specific disorders, but also possibly have adverse effects in common, as a result of pharmacological inhibition of gastric secretion. In this context the most serious hypothetical problem is the possibility that prolonged gastric secretory inhibition may result in the development of gastric cancer.11 12 Although no confirmation has been provided by rigorous surveillance during treatment,13 the matter has aroused widespread public concern. It has often been overlooked, however, that the hypothesised nitrosation involves the formation of nitrous acid and nitrous anhydride from nitrite, reactions which require the presence of hydrogein ions -that is, gastric acid,44 so that conditions associated with achlorhydria are unsatisfactory for the formation of nitroso compounds. On the other hand, nitrogen oxides react experimentally with aliphatic and heterocyclic amines in neutral or alkaline aqSueous conditions, while acidic pH is inhibitory.`This aspect of the formation of nitroso compounds appears not to have been satisfactorily studied in the context of intragastric contents and its role in the production of nitroso compounds in the gastric lumen during anti-ulcer therapy cannot be assessed at present.
It is, therefore, not surprising that some published studies seem to confirm each step of this hypothesis of achlorhydria-associated gastric carcinogenesis, but other studies provide contradictory information, 4649 so that factual evidence for the hypothesis remains uncertain. In any case, much more study is needed to confirm the allegedly increased production of possibly carcinogenic nitroso compounds in the stomach during treatment with gastric secretory inhibitors. It has been reported in a few studies that the concentration of nitroso compounds is increased in the gastric contents of individuals treated with gastric antisecretory drugs.50 32 41 So, of course, is the concentration of everything, because the secretion of diluting gastric juice is inhibited. There is no evidence that the production of nitroso compounds is increased. Indeed, in patients with atrophic gastritis in whom the production of nitroso compounds was studied by the administration of nitrate and proline, urinary excretion of nitrosoproline was not increased and the urinary levels were higphest in subjects with an intragastric pH of about 2. It is important that the problem should be studied properly in patients treated with antisecretory drugs, rather than verbally extrapolated as at present. This is because increased production of nitroso compounds (if it occurs) may be expected to magnify the risk not only to the stomach, but perhaps even more to the gall bladder, the urinary bladder, or the colon: it is in these organs that any absorbed and excreted nitroso compounds will be concentrated and remain in contact with the mucosa even longer than in the stomach. Clearly, both loxtidine and omeprazole produce gastric proliferation predisposing to, or actually causing, gastric neoplasia in the rat -but unless there are remakable strain differences, the trophic stimulus from these two powerful gastric inhibitors must be different. No information is available about the mechanism of the trophic effect of loxtidine.
Omeprazole produces hypergastrinaemia in man60
and it has been proposed that prolonged administration of omeprazole to rats results in continuous and long term hypergastrinaemia, which in turn produces the carcinoid tumours. It was previously reported that antral exclusion in rats stimulated the growth of the endocrine cells of the rat stomach61 62 and it had been argued that the associated hypergastrinaemia was responsible for the trophic stimulant effect on the gastric endocrine cells. In human atrophic gastritis there is also often proliferation of gastric mucosal endocrine cells63 and carcinoid tumours have been described in the stomach of patients with pernicious anaemia.64 65 Both of these gastric mucosal diseases are accompanied by hypergastrinaemia. While the proposed connection between hypergastrinaemia and the proliferation and neoplasia of the gastric endocrine cells is therefore possible, other trophic factors may also be involved. Thus it has been reported that antrocolic transposition in the rat is not accompanied by significant hypergastrinaemia, and yet there is marked growth of the duodenal mucosa in these animals,66 presumably triggered by another trophic factor. It has been suggested that in man, as in animals, the drug-induced achlorhydria results in hypergastrinaemia because the normal inhibition of gastrin release from the antral G cells is lacking, because acid (which inhibits gastrin release) is absent from the antral lumen. This point has not been confirmed experimentally. Moreover 78 with subsequent prophylactic gastrectomy has been put forward.
To summarise, therefore, the incidence of gastric cancer after gastrectomy differs in different parts of the world, some reported values reaching 21%.78 79 The incidence of gastric cancer after vagotomy is now being studied, but experimentally vagotomy predisposes to gastric cancer.80-82 A 2% incidence of gastric cancer after vagotomy has been recorded in patients,83 with an incidence of 2.2% after vagotomy and drainage,84 while about 2% of one series of patients with gastric cancer had previously had vagotomy.85 Even so, cancer ranks low in the list of causes of mortality after gastric surgery.
It is of course not surprising that controversy surrounds the incidence of gastric cancer after operations for ulcer disease. It is probably correct to conclude that gastric operations invariably render the gastric mucosa more susceptible to carcinogens. The actual incidence of gastric cancer will depend on the severity of the proliferative changes of the gastric mucosa (as 'initiated' cells may be desquamated if the degree of proliferation is too severe), as well as on the exposure of the abnormally proliferating gastric mucosa to organspecific genotoxic carcinogens. The presence and concentration of this type of carcinogen almost certainly varies greatly in different geographic areas and perhaps even in the same individual at different times and circumstances. The assessment of increased risk after gastric operations is further confounded by the statistical comparison of the incidence of gastric cancer in operated individuals with the risk in the 'control' general population. It seems likely that this type of analysis is poteitially misleading, because the gastric mucosa of patients with duodenal ulcer is 'resistant' to the development of gastritis,86 sO that gastric cancer in unoperated patients with duodenal ulcer is very rare,87 while the incidence of gastritis in the general population is high and increases with age. 
